Keywords: Gilead Sciences, Stribild, Quad, HIV-1 infection, USA, FDA

Gilead's Stribild, formerly "Quad," gets FDA nod

Article | 29 August 2012

Print This

The US Food and Drug Administration has approved US biotech firm Gilead Sciences’ (Nasdaq: GILD) Stribild (elvitegravir 150mg/cobicistat 150 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in